Presentations Will Include a Review of ANCHOR Study Data on KUR-502 from ASH Annual Meeting Webinar on Monday, December 13 th , at 9:00 a.m. ET BUFFALO, N.Y. , Nov. 30, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,

BUFFALO, N.Y. , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its Marketing Authorization

Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities Post hoc analysis of this subgroup of patients with hepatic impairment was conducted and showed a median survival rate of 18.9 months in patients treated with Oral

BUFFALO, N.Y. , Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau , CEO and Board

Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors BUFFALO, N.Y. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel

Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR). Updated data show continued favorable safety profile and encouraging anti-tumor activity in adult patients treated with low

Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M , up 9% year-over-year Company now expects full year product sales revenue in 2021 to decrease

BUFFALO, N.Y. , Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a

BUFFALO, N.Y. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) Patent protection helps validate the groundbreaking innovation of Dr.

BUFFALO, N.Y. , Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type A meeting

Klisyri has been approved for the treatment of actinic keratosis by the UK Medicines and Healthcare products Regulatory Agency and will initially be available for prescription in the UK and Germany AK is one of the most common diagnoses made by dermatologists in Europe and Almirall plans to a

Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies BUFFALO, N.Y. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc.

BUFFALO, N.Y. , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau , CEO and

Updated investors on FDA Type A Meeting for oral paclitaxel Klisyri ® approved by the European Commission in July 2021 KUR-501 GD2 CAR-NKT Phase 1 data in neuroblastoma presented at ASGCT 2021 Abstract for oral paclitaxel + pembrolizumab Phase 1 combination study accepted for ESMO Congress 2021

Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada BUFFALO, N.Y. , July 26, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of

BUFFALO, N.Y. , July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a

BUFFALO, N.Y. , July 19, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall

BUFFALO, N.Y. , July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company held a Type A

Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel Post-hoc subgroup efficacy analysis based on updated tumor subtypes in the oral paclitaxel phase III study demonstrated an improved response rate with oral paclitaxel

European Commission Decision Anticipated by July 2021 BUFFALO, N.Y. , May 21, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related

Data presented by investigators from the Texas Children’s Cancer Center One PR, one CR and four SDs out of 11 patients enrolled GD2 CAR NKT cells were well tolerated with no dose limiting toxicities CAR-NKT AUC normalized to disease burden (AUC/Curie score) was associated with response to therapy.

Plan to Request Type A Meeting with the FDA for Oral Paclitaxel by the End of May Klisyri® Launched in the U.S. in February 2021 Acquired Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform in May 2021 Management to Host Conference Call and Webcast at

Transformative, leading allogeneic NKT cell platform technology expands Athenex’s cell therapy development capability Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological and solid cancers,

BUFFALO, N.Y. , April 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a

Receipt of Complete Response Letter from the FDA for Oral Paclitaxel Plus Encequidar Klisyri® (tirbanibulin) received FDA approval and launched commercially on February 18, 2021 The New England Journal of Medicine published Phase III trial data on the efficacy and safety of Klisyri® Product sales

Conference call and webcast scheduled for today at 8:00 a.m. ET BUFFALO, N.Y. , March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and

BUFFALO, N.Y. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a

Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea . PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan , Singapore , and Malaysia Athenex’s

The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, developed by Athenex , received FDA

BUFFALO, N.Y. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board Chairman,

BUFFALO, N.Y. , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr.

BUFFALO, N.Y. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39 th